Pharmacy

DeliverCareRx Announces Grand Opening of New Hospice Pharmacy in Southern New Jersey

Tuesday, July 7, 2020 - 1:05pm

DeliverCareRx, a market leader in home delivery pharmacy services to both chronically and terminally ill hospice patients, has announced the grand opening of its Southern New Jersey facility located in West Deptford.

Key Points: 
  • DeliverCareRx, a market leader in home delivery pharmacy services to both chronically and terminally ill hospice patients, has announced the grand opening of its Southern New Jersey facility located in West Deptford.
  • The new facility will provide hospice pharmacy services and home delivery to all of its New Jersey hospice customers, as well as those hospice customers in the Greater Philadelphia area and Northeastern US.
  • DeliverCareRx is exclusively partnered with the industrys largest hospice pharmacy services provider, based out of Montgomery, AL.
  • DeliverCareRx is very excited to open our new state of the art New Jersey pharmacy solely specialized on serving hospices and hospice patients, said Dave Krishna RPh, President and CEO of DeliverCareRx.

McKesson Corporation to Announce First Quarter Fiscal 2021 Results on August 3, 2020

Monday, July 6, 2020 - 9:10pm

McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2021 financial results before market open on Monday, August 3, 2020.

Key Points: 
  • McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2021 financial results before market open on Monday, August 3, 2020.
  • The company will host a live webcast of the earnings conference call for investors at 8:00 AM Eastern Time to review its financial results.
  • The live webcast will be available on McKessons Investor Relations website at http://investor.mckesson.com , along with the companys earnings press release, financial tables and slide presentation.
  • McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology.

Avricore Health Amends Shares for Debt News Release

Monday, July 6, 2020 - 6:56pm

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level.

Key Points: 
  • Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level.
  • The Company's goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health.
  • www.avricorehealth.com
    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cell Expansion Market Worth $30.1 billion by 2025 - Exclusive Report by MarketsandMarkets™

Monday, July 6, 2020 - 1:30pm

CHICAGO, July 6, 2020 /PRNewswire/ -- According to the new market research report "Cell Expansion Marketby Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025", published by MarketsandMarkets,the Cell Expansion Marketis estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.

Key Points: 
  • CHICAGO, July 6, 2020 /PRNewswire/ -- According to the new market research report "Cell Expansion Marketby Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025", published by MarketsandMarkets,the Cell Expansion Marketis estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.
  • The media segment accounted for the largest share of the consumables segment in the market.
  • Based on end-users, the market has been segmented into research institutes, biotechnology & biopharmaceutical companies, cell banks, and other end users (includes hospitals, diagnostic centers, and laboratories).
  • In 2019, biotechnology & biopharmaceutical companies were the largest end-users in the Cell Expansion Market, and the trend is the same throughout the forecast period.

Cell Expansion Market Worth $30.1 billion by 2025 - Exclusive Report by MarketsandMarkets™

Monday, July 6, 2020 - 1:30pm

CHICAGO, July 6, 2020 /PRNewswire/ -- According to the new market research report "Cell Expansion Marketby Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025", published by MarketsandMarkets,the Cell Expansion Marketis estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.

Key Points: 
  • CHICAGO, July 6, 2020 /PRNewswire/ -- According to the new market research report "Cell Expansion Marketby Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025", published by MarketsandMarkets,the Cell Expansion Marketis estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%.
  • The media segment accounted for the largest share of the consumables segment in the market.
  • Based on end-users, the market has been segmented into research institutes, biotechnology & biopharmaceutical companies, cell banks, and other end users (includes hospitals, diagnostic centers, and laboratories).
  • In 2019, biotechnology & biopharmaceutical companies were the largest end-users in the Cell Expansion Market, and the trend is the same throughout the forecast period.

Global Active Pharmaceutical Ingredients (API) Market (2020 to 2026) - by Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Region - ResearchAndMarkets.com

Monday, July 6, 2020 - 1:26pm

The "Global Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • Global active pharmaceutical ingredients (API) market will reach $293.5 billion by 2026, growing by 7.2% annually over 2020-2026 owing to the rising need for medicine and pharmaceutical agents amid the COVID-19 pandemic.
  • Highlighted with 91 tables and 99 figures, this 190-page report Global Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Region: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire global API market and all its sub-segments through extensively detailed classifications.
  • The report is based on studies on 2015-2019 and provides forecast from 2020 till 2026 with 2019 as the base year.

EspeRare Receives FDA Breakthrough Therapy Designation for Investigational Prenatal Treatment ER-004 in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

Monday, July 6, 2020 - 12:00pm

These results, demonstrating that this prenatal treatment has a profound and life-changing effect on these infants,werepublished in the New England Journal of Medicine 1 .

Key Points: 
  • These results, demonstrating that this prenatal treatment has a profound and life-changing effect on these infants,werepublished in the New England Journal of Medicine 1 .
  • The FDA Breakthrough Therapy Designation intends to expedite the development and review of drugs for serious or life-threatening conditions.
  • Having the FDA Breakthrough Therapy Designation means scientists can aspire starting a clinical trial to confirm the findings for ER-004 and ultimately, if successful, make this treatment an option for families.
  • In Europe, the program receives support from the EMA's PRIME (Priority Medicines) and also the Orphan Drug Designation.

EspeRare Receives FDA Breakthrough Therapy Designation for Investigational Prenatal Treatment ER-004 in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

Monday, July 6, 2020 - 12:00pm

These results, demonstrating that this prenatal treatment has a profound and life-changing effect on these infants,werepublished in the New England Journal of Medicine 1 .

Key Points: 
  • These results, demonstrating that this prenatal treatment has a profound and life-changing effect on these infants,werepublished in the New England Journal of Medicine 1 .
  • The FDA Breakthrough Therapy Designation intends to expedite the development and review of drugs for serious or life-threatening conditions.
  • Having the FDA Breakthrough Therapy Designation means scientists can aspire starting a clinical trial to confirm the findings for ER-004 and ultimately, if successful, make this treatment an option for families.
  • In Europe, the program receives support from the EMA's PRIME (Priority Medicines) and also the Orphan Drug Designation.

Zhongchao Inc. Launches Patient Management Services

Monday, July 6, 2020 - 11:30am

The New Services will be branded as "Zhongxun" and carried out through the Company's wholly-owned subsidiary, Shanghai Zhongxun Medical Technology Co., Ltd.

Key Points: 
  • The New Services will be branded as "Zhongxun" and carried out through the Company's wholly-owned subsidiary, Shanghai Zhongxun Medical Technology Co., Ltd.
    "We are branching out the patient management team, whom we have been gradually building up since late 2018, from the MDMOOC platform and officially launching Zhongxun to provide focused patient management services.
  • With the combination of online service portal, offline call centers and dedicated field specialists, Zhongxun aims to work closely with hospitals, pharmacies, pharmaceutical enterprises and non-profit organizations and insurance companies (collectively, the "Involved Parties") in providing a whole range of patient management services including disease management, patient recruiting, patient counselling, in-home care assistance, clinical trial management, patient aid project management, insurance and payment solutions, and other value-added services.
  • "Patient management is a comprehensive system focusing on patient relationships, rather than just illnesses.
  • The Company also offers patient management services under its "Zhongxun" platform ( www.zhongxun.online ).

Greensill provides much needed cash to England's Pharmacies

Monday, July 6, 2020 - 10:09am

This will allow pharmacies to pay for medicines instantly rather than signing up to costly finance terms offered by pharmaceutical companies or banks.

Key Points: 
  • This will allow pharmacies to pay for medicines instantly rather than signing up to costly finance terms offered by pharmaceutical companies or banks.
  • The first of these payments was made this week to some 1,000 pharmacies Greensill works with across England.
  • A further 10,000-plus pharmacies now have the option to use this advanced payment programme.
  • Greensill has worked with over 1,000 pharmacies since July 2018, making more than 1.2 billion of supply chain finance payments a year to ensure these vital frontline community health providers are paid faster.